Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0492 • ACR Convergence 2021
Racial Differences in Glucocorticoid Use Among Medicaid Beneficiaries with Incident Systemic Lupus Erythematosus
Mia Chandler¹, Leah Santacroce², Karen Costenbader³, Rishi Desai⁴, Seoyoung Kim² and Candace Feldman², ¹Boston Children's Hospital, Brookline, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Belmont, MA, ⁴Brigham and Women's Hospital/Harvard Medical School, Boston, MA
Background/Purpose: Glucocorticoids (GCs) are an integral part of systemic lupus erythematosus (SLE) treatment. Long-term use of GCs is associated with adverse effects. This study evaluated…
Abstract Number: 0600 • ACR Convergence 2021
A Cohort Study of Retention in Ambulatory Lupus Care Among Medicare Patients with SLE-related Hospitalizations
Maria Schletzbaum¹, Carlos Torres², Amy Kind², Andrea Gilmore Bykovskyi³, Ann Sheehy² and Christie Bartels², ¹University of Wisconsin School of Medicine and Public Health, Middleton, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI, ³University of Wisconsin - Madison School of Nursing, Madison, WI
Background/Purpose: In other conditions that require chronic management, poor retention in ambulatory care is associated with adverse outcomes. We previously identified that living in the…
Abstract Number: 0777 • ACR Convergence 2021
Potential Biomarkers of Cognitive Impairment in the Context of Childhood-Onset Systemic Lupus Erythematosus
Santiago Arciniegas¹, Sarah Mossad², Tala El Tal³, Lawrence Ng⁴, Paris Moaf⁴, Helen Branson⁴, Adrienne Davis⁴, Linda Hiraki⁴, Deborah Levy⁴, Ashley Danguecan² and Andrea Knight², ¹University of Toronto/The Hospital for Sick Children, Toronto, ON, Canada, ²Hospital for Sick Children, Toronto, ON, Canada, ³University of Toronto/Hospital for Sick Children, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Cognitive complaints are common in children with childhood-onset systemic lupus erythematosus (cSLE), but neuropsychiatric lupus (NPSLE) remains challenging to diagnose and treat. To increase…
Abstract Number: 0868 • ACR Convergence 2021
Cell-bound Complement Activation Products (CB-CAPs) Predicts Type 1 SLE Activity
Jennifer Rogers¹, Rory Bloch², Amanda Eudy¹, David Pisetsky³, Roberta Alexander², John Conklin², Kai Sun¹, Rebecca Sadun¹, Lisa Criscione-Schreiber⁴, Jayanth Doss¹ and Megan Clowse⁵, ¹Duke University, Durham, NC, ²Exagen Inc., Vista, CA, ³Duke University Medical Center, Durham, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵Duke University, Chapel Hill, NC
Background/Purpose: SLE is a multisystem autoimmune disease that displays diverse manifestations that can be categorized into two broad types. Type 1 SLE activity includes inflammatory…
Abstract Number: 0885 • ACR Convergence 2021
SLE Phenotypes Formed from Machine Learning and Their Associations with Cognitive Impairment
Michelle Barraclough¹, Lauren Erdman², Andrea Knight³, Juan Diaz-Martinez⁴, Kathleen Bingham⁵, Jiandong Su⁶, Mahta Kakvan⁶, Maria Tartaglia⁶, Lesley Ruttan⁵, Joan Wither⁶, May Choi⁷, Marvin Fritzler⁸, Dennisse Bonilla⁶, Dorcas Beaton⁹, Ben Parker¹⁰, Robin Green⁶, Patricia Katz¹¹, Ian N. Bruce¹⁰ and Zahi Touma¹², ¹University of Manchester, University Health Network, Toronto, ON, Canada, ²The Hospital of Sick Children, Toronto, ON, Canada, ³Hospital for Sick Children, Toronto, ON, Canada, ⁴UHN, Toronto, ON, Canada, ⁵University of Toronto, University Health Network, Toronto, ON, Canada, ⁶University Health Network, Toronto, ON, Canada, ⁷Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹Institute for Work & Health, Toronto, ON, Canada, ¹⁰University of Manchester, Manchester, United Kingdom, ¹¹University of California San Francisco, San Francisco, CA, ¹²University of Toronto, Mississauga, ON, Canada
Background/Purpose: Cognitive impairment (CI) in SLE is a significant problem with limited treatment options. This is in part due to the uncertainty regarding the multifaceted…
Abstract Number: 0972 • ACR Convergence 2021
Hypoxia Promotes the Expression of ADAM9 by Tubular Epithelial Cells Which Enhances TGF-β1 Activation and Promotes Tissue Fibrosis in Lupus Nephritis
Masataka Umeda¹, Abhigyan Satyam¹, Nobuya Yoshida¹, Rhea Bhargava¹, Ryo Hisada¹, Simin Jamaly¹, Caroline Owen² and George Tsokos³, ¹Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ³BIDMC, Boston, MA
Background/Purpose: Enhanced expression of transforming growth factor-beta (TGF-β) in the kidneys of patients with lupus nephritis (LN) can lead to progressive fibrosis, resulting in end-organ…
Abstract Number: 1099 • ACR Convergence 2021
Characteristics and Outcomes of Myocardial Infarction in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Gout and Osteoarthritis Patients Using the National Inpatient Sample Database from 2002-2018
Sonia Gupta¹, Vinay thallapally², Sarah Aurit², Rouhin sen³ and Joseph Nahas², ¹Creighton University School of Medicine, Omaha, NE, ²Creighton University, Omaha, NE, ³Colorado University Anschutz Medical Campus, Denver, CO
Background/Purpose: Patients with the autoimmune rheumatic disease have an increased risk of acute myocardial infarction (MI). Our study was designed to compare the prevalence, characteristics…
Abstract Number: 1265 • ACR Convergence 2021
Paradoxical Effect of Vitamin D on Bone Mineral Density in SLE
Michelle Petri¹, Jessica Li² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: Osteoporosis with fractures is consistently one of the top three items in the SLICC/ACR Damage Index in cohort studies internationally. As vitamin D insufficiency…
Abstract Number: 1281 • ACR Convergence 2021
Longitudinal Association of Baseline Frailty with Patient-Reported Outcome Measures
Sarah Lieber¹, Musarrat Nahid², Mangala Rajan², Medha Barbhaiya¹, Lisa Sammaritano¹, Robyn Lipschultz¹, Myriam Lin¹ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY
Background/Purpose: Frailty has been associated with disability and mortality in systemic lupus erythematosus (SLE). While frailty is known to be associated with worse patient-reported outcome…
Abstract Number: 1297 • ACR Convergence 2021
Factors Associated with Employment and Work Disability in Patients with SLE: A Nested Case-control Study
Connor Maddock¹, Behdin Nowrouzi-Kia², Jiandong Su³ and Zahi Touma⁴, ¹University College Dublin, Dublin, Ireland, ²University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Mississauga, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organ systems and can vary in its manifestations between individuals. SLE…
Abstract Number: 1459 • ACR Convergence 2021
Attainment of the Lupus Low Disease Activity State in Response to Anifrolumab in 2 Phase 3 Trials
Eric Morand¹, Gabriel Abreu², Richard Furie³ and Raj Tummala⁴, ¹Monash University, Melbourne, Australia, ²BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ³Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ⁴BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD
Background/Purpose: The Lupus Low Disease Activity State (LLDAS), a treat-to-target (T2T) endpoint for SLE, is prospectively validated as protective from flares and damage accrual.1 LLDAS…
Abstract Number: 1491 • ACR Convergence 2021
Single-cell Analysis of Paired Skin and Blood Samples from Patients with SLE and Cutaneous Lupus Suggests CD16+ DCs Arise from Non-classical Monocytes That Enter Nonlesional Skin, Undergo Type I IFN Education, and Engage in Extensive Crosstalk with Diverse Immune and Stromal Cell Types
Allison Billi¹, Feiyang Ma², Olesya Plazyo³, Grace Hile³, Xianying Xing³, Mehrnaz Gharaee-Kermani⁴, Rachael Wasikowski³, Lam Tsoi³, Matteo Pellegrini², Robert L. Modlin², Johann Gudjonsson¹ and J. Michelle Kahlenberg³, ¹Department of Dermatology, University of Michigan, Ann Arbor, MI, ²University of California Los Angeles, Los Angeles, CA, ³University of Michigan, Ann Arbor, MI, ⁴Internal Medicine - Division of Rheumatology and Department of Dermatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Cutaneous lupus erythematosus (CLE) is an incompletely understood autoimmune disease that can occur in isolation or in the context of SLE. CLE is often…
Abstract Number: 1592 • ACR Convergence 2021
ACT for Lupus: Pilot Study of a Novel Acceptance and Commitment Therapy (ACT) Online Program to Support Patients with Lupus During the COVID-19 Pandemic
Tessa Englund¹, Saira Sheikh², Becki Cleveland¹, Emily McCormick¹, Crystal Schiller³ and Teresa Dickson¹, ¹Thurston Arthritis Research Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, ²University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, ³University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic disease associated with significant symptom burden, including fatigue, anxiety, depression, pain, and negative impacts on health-related quality…
Abstract Number: 1726 • ACR Convergence 2021
A Pregnancy Planning Quality Score to Assess a Systematic Intervention to Improve Pregnancy Planning for Women with SLE
Catherine Sims¹, Amanda Eudy¹, Jayanth Doss¹, Lisa Criscione-Schreiber², Kai Sun², Rebecca Sadun¹, Jennifer Rogers² and Megan Clowse³, ¹Duke University, Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Duke University, Chapel Hill, NC
Background/Purpose: The safest pregnancies for women with SLE coincide with periods of disease quiescence maintained by pregnancy-compatible medications. In the US, Black women are more…
Abstract Number: 1750 • ACR Convergence 2021
Itolizumab, a Novel anti-CD6 Therapy, in Systemic Lupus Erythematosus Patients: Interim Safety Results from the Phase 1b EQUALISE Dose-escalation Study
Kenneth Kalunian¹, Richard Furie², Jai Radhakrishnan³, Vandana Mathur⁴, Krishna Polu⁴, Stephen Connelly⁴, Joel Rothman⁴, Cherie Ng⁴, Leslie Chinn⁵, Maple Fung⁶, Dolca Thomas⁷ and Chaim Putterman⁸, ¹UC San Diego, La Jolla, CA, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³Columbia University, New York, NY, ⁴Equillium, Inc., La Jolla, CA, ⁵Equillium, Inc., South San Francisco, CA, ⁶Equillium, Inc., San Diego, CA, ⁷Equillium, Inc., Brooklyn, NY, ⁸Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: CD6, a co-stimulatory receptor predominantly expressed on T cells, promotes CD4+ T cell proliferation and differentiation into Th1/Th17 cells. The CD6 ligand, activated leukocyte…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].